HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials. - Abuhelwa AY; Almansour SA; Al-Shamsi HO; Abuhelwa Z; Ziade MA; McKinnon RA; Sorich MJ; Hopkins AM (Journal of the National Comprehensive Cancer Network : JNCCN, 2026)